The impact of thrombosis and bleeding among patients with Myeloproliferative Neoplasm: Systematic Review and Meta Analysis.

Background: Thrombosis and bleeding are the most common complications which contribute to significant morbidity and mortality of myeloproliferative patients. This study aimed to find out the incidence of thrombotic and bleeding events during diagnosis and follow up among patients with myeloproliferative neoplasm. This might help in the early detection of thrombosis and bleeding and prevention of such complications for MPN patients. Methods: A systematic review and meta-analysis was conducted to assess the incidence of thrombosis and bleeding. Data extracted from the literatures in Google scholars, Mendeley, PubMed, and EMBASE databases. Studies that had thrombosis and/or bleeding reports with any types of myeloproliferative neoplasm were included in this study. We used random effect model to estimate the odd ratio, relative risk and risk difference with 95%CI of each studies and the pooled results based on Cochrane methods of Revman. A funnel plot and I2 test checked to see the publication bias and heterogeneity respectively. Results: Nineteen studies with 14706 participants that had fitted the inclusion criteria were included in the overall thrombosis study. Five studies (n=931) included for incidence thrombosis at diagnosis and follow up. The pooled overall frequency thrombosis was 18.6%. The pooled incidence of thrombosis at diagnosis was 26.5% and odds ratio (OR= 3.17,95%CI 0.96 to10.43); relative risk (RR= 2.07,95%CI 0.98 to 4.34); risk difference (RD=21%, 95%CI -0.05 to 0.48, high certainty). Thrombosis had significant differences during diagnosis and follow up. A history of thrombosis, age >60years, and smoking were some of the risk factors for thrombosis. Conclusions: Based on the findings, thrombosis and bleeding are the highest complications occurred among myeloproliferative neoplasm patients. This problem is also common both during diagnosis and follow up of MPN patients. Early detection and follow up is needed to prevent MPN complications. Keywords: Thrombosis, bleeding, MPN, diagnosis, follow up.


Introduction
Myeloproliferative disorders are a group of hematologic malignancies in which the bone marrow makes too many red blood cells, white blood cells, and platelets. They comprise several clonal hematologic diseases that arise from a transformation in a hematopoietic stem cell. myeloproliferative neoplasm is complicated and transformed into myelofibrosis or leukemia 13 . The three main Philadelphia negative myeloproliferative disorders are polycythaemia Vera, essential thrombocythemia, and idiopathic myelofibrosis which are characterized by various combinations of erythrocytosis, leucocytosis and thrombocytosis 1 .
Polycythaemia Vera is a disease in which too many red blood cells are made in the bone marrow.

Whereas primary myelofibrosis from abnormal blood cells and fibbers build up inside the bone marrow.
Essential thrombocythemia causes an abnormal increase in the number of platelets made in the blood and bone marrow. Symptoms-Headache, Burning or tingling in the hands or feet, Redness, and warmth of the hands or feet, vision, or hearing problems 4,11,12 .
The annual incidences of both polycythaemia Vera and essential thrombocythemia are 1 to 3 cases per 100,000 population; myelofibrosis is less common 5 .
The underlying causes of myeloproliferative neoplasms are largely unknown. A mutation in the gene for Janus kinase 2, (JAK2)V617F, is present in most erythropoietin-independent erythroid colonies in polycythaemia Vera. The mutation is present in 95% of polycythaemia Vera patients and in approximately 50% of essential thrombocythemia and primary myelofibrosis patients 7 .
The increase of the thrombotic risk observed at progressively higher haematocrit values parallels blood viscosity, although also biochemical changes in the cell membrane and content could contribute to . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint rheological abnormalities and this may lead to myeloproliferative neoplasm patient's complication and morbidity and mortality 8 . Therapy in both PV and ET is targeted to prevent thrombohemorrhagic Complications. On the other hand, thrombosis, leucocytosis, and age are the risk factors for the survival of patients with essential thrombocythemia and polycythaemia vera 9 .
Thrombosis and bleeding are the most common complications which contribute to significant morbidity and mortality for myeloproliferative patients 10 .
Arterial and the venous are the systems for myeloproliferative neoplasm complications to thrombosis. The Objective of this study is to find out the frequency of thrombotic and bleeding events for Myeloproliferative neoplasm patients. Early detection and prevention of thrombosis and bleeding complication is important to reduce mortality of patients with MPN.

Methods and Materials:
Literature was searched by using Google scholars, Mendeley, PubMed, and EMBASE databases for studies on thrombosis and myeloproliferative neoplasm. Terms used to search were "thrombosis, bleeding and myeloproliferative neoplasm". By using the terms, we got a total of 3144 articles; in Google scholar 2340 articles, in PubMed 287 articles, in Mendeley 190 articles and in EMBASE 327 articles (recorded as #1). Finally, thirty-two articles were selected and included in this study, which were fitted the inclusion criteria.
We filtered human studies with the English language and sorted by best match and recent studies. A Systematic Review and Meta-analysis were done based on the PRISMA guideline. A Citation and references were managed by Mendeley desktop. All types of studies having thrombosis and myeloproliferative neoplasm and their clinical characteristics. We compared studies, patients with myeloproliferative neoplasm with thrombosis, and without thrombosis. Age and sex differences of thrombosis also considered. We used relative risk (RR) to measure the effect size difference and confidence interval for each study. We also used a random effect to measure the relative weight assigned to each study. Publication bias was checked by using a funnel plot.
Heterogeneity between studies was calculated using the I 2 test.

The inclusion criteria:
Patients who were diagnosed MPN (either PV, ET and PMF or all types) Studies that have information about thrombosis, and/or bleeding in patients with myeloproliferative neoplasm, studies that have information about the study participants' age, and sex. Whereas studies that . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint have not full information for our study, or studies that did not report thrombosis, and/or bleeding among myeloproliferative disorder were excluded.

RESULTS
Data extraction and the selection of literature were conducted as shown by the following diagram.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020.    CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint Thrombosis and bleeding are the most common complication that cause the morbidity and mortality of patients with myeloproliferative neoplasm 14,16,19,21,22,23,29,29,37,38,38,40,41 . This review showed that among a total of 14706 MPN patients, 2735 thrombotic events happened and there are also many bleeding recorded. Venous and arterial thrombosis has been the highest prevalence site of events. There are many contributing factors for such complication. Age, previous thrombosis, late diagnosis and follow up are some of them 17, 32 . They have different site of thrombosis and the site of bleeding.
More than 9.5x10 9 L white blood cells which has lowered by hydroxyurea therapy is associated with thrombosis 19 . Among MPN patients, the incidence of thrombosis was high in PV and ET patients. It had both arterial and venous event. Whereas the incidence of bleeding was high in patients with PMF. Thrombosis and bleeding had been the highest burden recorded in Ph negative MPN patients 30 .
Mesenteric vein and splenic venous thrombosis found to be greater and BCS, previous thrombosis history, splenomegaly, and leukocytosis are the associated factors. Extracranial and intracranial bleeding have the major one 15 .
The PV and ET therapies use to lower thrombosis complication. Age greater than 60 years and previous thrombosis are vascular risk predictors 33 .
Bleeding occur during follow up among patients with ET and PMF and, diagnosis of PMF, leukocytosis, aspirin therapy and past history of hemorrhage are bleeding predictors 20 . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint Ninety two percent of the investigated cases have vascular risk factors and the complication occur within 12 months after ET and PV diagnosis 34 . The incidence of arterial and venous thrombosis is increasing across in all age groups of MPN patients in comparison with the controls. The thrombosis rate is highest after diagnosis and then it decreases there after 13 .
The prevalence of CALR mutations is lower among MPN, BCS and PVT patients, and thrombosis rate is lower in CALR Mutation as compared with JAK2V617F mutation 35 .
The mortality rate of MPN patients with JAk2V617F mutation are higher. The length of KAK2V617F mutation development is 21 months during the follow up. Thrombosis free survival is smaller and there is no bleeding incidence difference between groups 24 .
The thrombosis of splenic vein is correlated with MPN, eighty percent of thrombosis occurred among patients with MPN. Esophageal variceal bleeding recorded due to portal hypertension 28 .
Among a study of 44 PVT and MPN patients, the median age during diagnosis was forty-eight years and most of the patients were females. Eleven percent and twenty three percent of the patients had previous thrombosis and family history of thrombosis respectively. Many factors that causes venous thrombosis in addition to MPN 26  Limitation of the study: different study designs had included in this study, which may reduce strength of the evidence.
Literature search were limited with English language, this also reduce the access of studies in other language. And unpublished information had not included in this study.

CONCLUSIONS
Bleeding and thrombosis have the common complication faced among Myeloproliferative neoplasm patients. The incidence of thrombosis is the major problem both during diagnosis and follow up. Age greater than 60 years, previous thrombosis, leukocytosis and other factors are associated with thrombosis among patients MPN.

Conflict of interest
The authors declare no conflict of interest.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . https://doi.org/10.1101/2020.08.27.20182535 doi: medRxiv preprint